BioStem's BioRetain Allograft Shows 71% Higher Healing Rate in Diabetic Foot Ulcer Trial
核心洞察
BioStem Technologies reported that its BioRetain (搜索)-processed amnion chorion allograft (搜索) achieved a 53% healing probability versus 31% for standard care in a randomized controlled trial of 71 diabetic foot ulcer patients.
The multicenter BR-AC (搜索)-DFU-101 study enrolled only hard-to-heal wounds by excluding patients who showed greater than 30% wound size reduction during a 2-week standard care run-in period.
The trial followed FDA guidance for cutaneous ulcers and required wounds to remain closed for 4 weeks after initial closure to qualify as achieving lasting wound closure.
BioStem Technologies announced positive results from its randomized controlled trial evaluating BioRetain (搜索)-processed amnion chorion (BR-AC (搜索)) allografts for treating diabetic foot ulcers (搜索), demonstrating a 53% probability of healing compared to 31% with standard care alone. The results, published in the International Journal of Tissue Repair, represent nearly twice the likelihood of achieving lasting wound closure in patients with hard-to-heal diabetic foot ulcers.
Rigorous Trial Design Targets Difficult Cases
The BR-AC (搜索)-DFU-101 study was conducted at 11 sites across the United States, enrolling 71 patients with Wagner 1 or 2 diabetic foot ulcers (搜索) over a 12-week treatment period. The trial incorporated a unique 2-week run-in period to evaluate patient response to standard care alone, with any patient experiencing greater than 30% wound size reduction excluded from randomization.
"The patient selection criteria ensured that only those patients with the hardest-to-heal wounds were enrolled, and the definition of closure followed the 2006 FDA guidance for cutaneous ulcers, the most rigorous standards established," explained Dr. Bert Slade, Chairman of BioStem's Medical Advisory Board.
The study required wounds to remain closed for 4 weeks following initial closure to qualify as achieving lasting closure, emphasizing durability of treatment outcomes rather than temporary healing.
Clinical Significance in High-Risk Population
Diabetic foot ulcers (搜索) represent a significant clinical challenge, affecting approximately 15% of people with diabetes (搜索) according to the American Podiatric Medical Association (搜索). The condition carries substantial risks, with 6% of patients requiring hospitalization due to infections or complications, and between 14% and 24% of individuals ultimately requiring amputation.
Recent data from Global Data Plc (搜索). revealed that 2.2 million patients received treatment for diabetic foot ulcers (搜索) in 2023, with numbers projected to rise due to an aging population and increased prevalence of diabetes (搜索), peripheral vascular disease (搜索), and impaired wound healing. The economic burden reaches $9 billion to $13 billion annually in the United States alone.
BioRetain Technology Platform
BioStem's allografts utilize the company's proprietary BioRetain (搜索) processing method, which maintains native tissue components including the structure and matrix found in fresh perinatal tissue. The patented six-step process preserves natural integrity of amniotic tissue components while serving as a protective covering to optimize the wound treatment environment.
"Previously reported comparisons of BioRetain (搜索) versus competitive technologies have demonstrated its superiority in retaining the natural structural and molecular composition of the native tissue," said Jason Matuszewski, CEO and Chairman of BioStem Technologies. "This study reinforces the clinical performance of our technology."
Future Research and Commercial Implications
BioStem continues enrollment in a separate study targeting venous leg ulcers (搜索) using BR-AC (搜索) technology. Future publications from the current study will address secondary outcome measures including treatment group differences in wound closure timing, wound area and volume changes, and the number of BR-AC applications required to achieve complete wound closure.
The company's quality management systems are accredited by the American Association of Tissue Banks (搜索) and adhere to current Good Tissue Practices, with all placental allografts processed at BioStem's FDA-registered facility in Pompano Beach, Florida.